Bad Homburg v.d. Höhe, August 24, 2022 – The ForTra gGmbH für Forschungstransfer der Else Kröner-Fresenius-Stiftung (ForTra) is supporting the production of new pharmaceutical candidates under GMP conditions for direct use in first-in-human clinical studies involving patients with a total of three million euros.
The implementation of clinical studies is a cost-intensive and mandatory development phase on the path to translating new medications into clinical application. “We have published a special call for proposals with this in mind. It is intended to help individual innovative projects with the production of new pharmaceutical drugs under Good Manufacturing Practice (GMP) conditions, and consequently enable the subsequent implementation of a clinical study involving patients,” explains Prof. Dr. Martin Zörnig, CEO of ForTra.
The entire production process or individual parts thereof shall be funded for a variety of active compound classes, preferentially for molecules from the area of synthetic chemistry (“small molecules”, peptides, oligonucleotides, RNA, etc.). Up to three million euros are envisaged for the whole call for proposals.
Eligible to submit proposals for non-profit funding by ForTra are research scientists employed by academic research facilities (hospital clinics, research institutes, etc.) or other non-profit scientific entities.
The selection procedure for funded projects occurs in two steps: Starting now, proposal outlines can be be submitted via email until September 23, 2022 to email@example.com
As the next step, an external panel of expert reviewers uses the outlines to identify individual projects, whose project managers are subsequently requested to submit a full application. Following assessment and recommendation of the full applications by the expert reviewers, the Foundation Board at EKFS will issue its approvals for funding to ForTra, presumably by the end of 2022.
ForTra gGmbH für Forschungstransfer der Else Kröner-Fresenius-Stiftung (EKFS)
ForTra is a recognized non-profit subsidiary of the foundation Else Kröner-Fresenius-Stiftung in compliance with German tax law regulations. The purpose of the German limited liability company is the advancement of medical science and research along with the promotion and support of public health through the translation of medical research findings into clinical application to the benefit of both patients and public healthcare.
Prof. Dr. Martin Zörnig
CEO of ForTra gGmbH für Forschungstransfer der EKFS
Tel.: +49 6172 8975-12
Else Kröner-Fresenius-Stiftung (EKFS) – Advancing research. Helping people.
Else Kröner-Fresenius-Stiftung is a non-profit foundation dedicated to the funding and advancement of medical research and the support of humanitarian projects. To date the foundation has funded around 2,300 projects. With an annual funding volume currently amounting to over 60 million euros it is the largest foundation in Germany that actively funds and supports medicine. You can find more information at: www.ekfs.de/en
Presse- und Öffentlichkeitsarbeit
Tel.: + 49 6172 8975-24